SK15662001A3 - Nové zlúčeniny - Google Patents

Nové zlúčeniny Download PDF

Info

Publication number
SK15662001A3
SK15662001A3 SK1566-2001A SK15662001A SK15662001A3 SK 15662001 A3 SK15662001 A3 SK 15662001A3 SK 15662001 A SK15662001 A SK 15662001A SK 15662001 A3 SK15662001 A3 SK 15662001A3
Authority
SK
Slovakia
Prior art keywords
group
amino
compound
tert
formula
Prior art date
Application number
SK1566-2001A
Other languages
English (en)
Slovak (sk)
Inventor
Marcel Linschoten
Magnus Polla
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SK15662001A3 publication Critical patent/SK15662001A3/sk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • A61K38/57Protease inhibitors from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/132Amines having two or more amino groups, e.g. spermidine, putrescine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/09Diamines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55Acids; Esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SK1566-2001A 1999-05-03 2000-05-03 Nové zlúčeniny SK15662001A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9901572A SE9901572D0 (sv) 1999-05-03 1999-05-03 New compounds
PCT/SE2000/000846 WO2000066550A1 (en) 1999-05-03 2000-05-03 New compounds

Publications (1)

Publication Number Publication Date
SK15662001A3 true SK15662001A3 (sk) 2002-09-10

Family

ID=20415425

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1566-2001A SK15662001A3 (sk) 1999-05-03 2000-05-03 Nové zlúčeniny

Country Status (23)

Country Link
US (2) US7354895B1 (ro)
EP (1) EP1180099A1 (ro)
JP (1) JP4270759B2 (ro)
KR (1) KR20020010631A (ro)
CN (1) CN1358187A (ro)
AR (1) AR028826A1 (ro)
AU (1) AU4447100A (ro)
BR (1) BR0010256A (ro)
CA (1) CA2371215A1 (ro)
CZ (1) CZ20013931A3 (ro)
EE (1) EE200100573A (ro)
HK (1) HK1042493A1 (ro)
HU (1) HUP0202379A3 (ro)
IL (1) IL145953A0 (ro)
IS (1) IS6141A (ro)
MX (1) MXPA01011043A (ro)
NO (1) NO20015374L (ro)
PL (1) PL356140A1 (ro)
SE (1) SE9901572D0 (ro)
SK (1) SK15662001A3 (ro)
TR (1) TR200103144T2 (ro)
WO (1) WO2000066550A1 (ro)
ZA (2) ZA200108966B (ro)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3400798B2 (ja) 1999-09-14 2003-04-28 明治製菓株式会社 カルボキシペプチダーゼb阻害活性を有するホスホン酸誘導体
IL153225A0 (en) * 2000-08-17 2003-07-06 Pfizer Substituted imidazoles as tafia inhibitors
SE0103272D0 (sv) * 2001-09-28 2001-09-28 Astrazeneca Ab Chemical compounds
CA2472238A1 (en) * 2002-01-22 2003-07-31 Pfizer Inc. 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors
BR0307033A (pt) 2002-01-22 2004-12-07 Pfizer ácidos 3-(imidazolil)-2-aminopropanóicos para o uso como inibidores tafi-a para o tratamento de doenças trombóticas
US6713496B2 (en) 2002-01-22 2004-03-30 Pfizer Inc 3-(imidazolyl)-2-alkoxypropanoic acids
MXPA04009125A (es) 2002-03-21 2004-12-07 Schering Ag Inhibidores de carboxipeptidasa b plasmatica.
AU2009310841A1 (en) 2008-10-29 2010-05-06 Taisho Pharmaceutical Co., Ltd. Compounds having TAFIa inhibitory activity
SG11202108503PA (en) * 2019-02-08 2021-09-29 Astrazeneca Ab Arginase inhibitors and methods of use thereof
CN111110837B (zh) * 2020-01-06 2022-11-25 中国人民解放军陆军军医大学 一种羧肽酶抑制剂在制备预防重症致死性轮状病毒感染药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2516307A (en) * 1949-01-06 1950-07-25 Gen Mills Inc Vinyl resins plasticized with cyano esters
US4560680A (en) * 1982-03-15 1985-12-24 E. R. Squibb & Sons, Inc. Aminoalkyl and related substituted phosphinic acid angiotensin converting enzyme inhibitors
US4849414A (en) * 1986-06-11 1989-07-18 E. R. Squibb & Sons, Inc. Substituted aminoalkanoylaminoalkyl phosphonate angiotensin converting enzyme inhibitors
FR2610951B1 (fr) * 1987-02-17 1989-05-05 Aerospatiale Armature tissee pour materiau composite
IL86951A (en) * 1987-07-06 1996-07-23 Procter & Gamble Pharma Methylene phosphonoalkylphosphinates and pharmaceutical preparations containing them
CZ282889B6 (cs) * 1991-12-17 1997-11-12 Procter And Gamble Pharmaceuticals, Inc. Použití difosfonátů a parathormonu pro výrobu léčiva, které se používá pro léčení osteoporosy
US5550119A (en) * 1995-03-02 1996-08-27 Ciba-Geigy Corporation Phosphono substituted tetrazole derivatives as ECE inhibitors
US5672592A (en) * 1996-06-17 1997-09-30 Guilford Pharmaceuticals Inc. Certain phosphonomethyl-pentanedioic acid derivatives thereof
JP3440305B2 (ja) * 1997-04-02 2003-08-25 高砂香料工業株式会社 7−(n−置換アミノ)−2−フェニルヘプタン酸 エステル誘導体及び該誘導体の製造方法
NZ337336A (en) 1997-02-27 2001-05-25 American Cyanamid Co N-hydroxy-2-(alkyl, aryl or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
SE9901573D0 (sv) * 1999-05-03 1999-05-03 Astra Ab New compounds
AR023819A1 (es) * 1999-05-03 2002-09-04 Astrazeneca Ab FORMULACIoN FARMACEUTICA, KIT DE PARTES Y UTILIZACION DE DICHA FORMULACION
JP3400798B2 (ja) * 1999-09-14 2003-04-28 明治製菓株式会社 カルボキシペプチダーゼb阻害活性を有するホスホン酸誘導体

Also Published As

Publication number Publication date
NO20015374D0 (no) 2001-11-02
EE200100573A (et) 2003-02-17
PL356140A1 (en) 2004-06-14
JP2002543179A (ja) 2002-12-17
SE9901572D0 (sv) 1999-05-03
AU4447100A (en) 2000-11-17
ZA200108967B (en) 2003-01-30
BR0010256A (pt) 2002-02-13
CZ20013931A3 (cs) 2002-04-17
EP1180099A1 (en) 2002-02-20
CN1358187A (zh) 2002-07-10
US20060079484A1 (en) 2006-04-13
IL145953A0 (en) 2002-11-10
IS6141A (is) 2001-11-01
TR200103144T2 (tr) 2004-11-22
NO20015374L (no) 2001-11-02
US7354895B1 (en) 2008-04-08
KR20020010631A (ko) 2002-02-04
WO2000066550A8 (en) 2001-01-25
AR028826A1 (es) 2003-05-28
JP4270759B2 (ja) 2009-06-03
HK1042493A1 (zh) 2002-08-16
CA2371215A1 (en) 2000-11-09
MXPA01011043A (es) 2002-06-04
WO2000066550A1 (en) 2000-11-09
ZA200108966B (en) 2003-01-30
HUP0202379A2 (hu) 2002-12-28
US7423012B2 (en) 2008-09-09
HUP0202379A3 (en) 2003-04-28

Similar Documents

Publication Publication Date Title
US7423012B2 (en) Phosphinyloxy, oxime and carboxylic acid derivatives which are useful as carboxypeptidase U inhibitors
US7071175B1 (en) Pyridine mercapto carboxylic acids as carboxypeptidase U inhibitors
US5736521A (en) Method of treatment and prophylaxis of arterial thrombosis
EP0910573B1 (en) New amino acid derivatives and their use as thrombin inhibitors
AU2006235835B2 (en) Non-covalent inhibitors of urokinase and blood vessel formation
US20090012087A1 (en) New Aza-Bicyclohexane Compounds Useful As Inhibitors Of Thrombin
KR100347646B1 (ko) 매트릭스메탈로프로테아제억제제
RU2248359C2 (ru) Ингибиторы фактора viia
SK286856B6 (sk) N-Guanidinoalkylamidy, spôsob ich prípravy, použitie a farmaceutické prostriedky, ktoré ich obsahujú
EP0322633A1 (en) Mercapto-acylamino acid antihypertensives
KR100483869B1 (ko) 신규한 아미노산 유도체 및 트롬빈 억제제로서의 그의 용도
CZ20002070A3 (cs) Nové sloučeniny